Close
Date: 31st March - 1st April 2016
Location:
The Atrium, Royal Free Hospital, Pond Street
London, NW3 1NL
Fees: Consultants / Surgeons - £120 | Trainees / Nurses / Scientists £65
An outstanding educational programme covering the clinical management, current areas of controversy and the latest in fundamental research in the field of Hepatocellular Cancer.
Programme organisers
Professor Tim Meyer
Professor of Experimental Cancer Medicine and Consultant in Medical Oncology
Royal Free Hospital and UCL Cancer Institute, London
Dr James O’Beirne
Consultant in Hepatology, Royal Free Hospital, London
Dr Aileen Marshall
Consultant in Hepatology, Royal Free Hospital, London
Professor Massimo Pinzani
Consultant Hepatologist, Sheila Sherlock Chair in Hepatology
UCL Institute for Liver and Digestive Health, University College London
Conference coordinator
Dr Mekala Gunaratnam
UCL Experimental Cancer Medicine Centre
UCL Cancer Institute, London
Who is this conference for?
Oncologists, Hepatologists, Gastroenterologists and Surgeons, Non-medical Health Professionals and Basic Scientists interested in liver cancer.
Conference programme
The programme aims to cover a range of topics to give a broad overview of the latest thinking and advances in the field of Hepatocellular carcinoma. Lectures covering various medical disciplines will be delivered by leading experts and we have also included lectures in areas of emerging interest such as immunotherapy and epigenetics. Current areas of controversy such as the role of biopsy and surveillance will be covered in the format of debates with the opportunity for audience participation. Finally, we have introduced a ‘live’ multidisciplinary meeting in which a panel of experts will be presented with a series of cases and asked to define and justify the treatment plans.
Learning objectives
- Gain an understanding of the latest innovations for the treatment of hepatocellular carcinoma.
- Explore advances in the molecular biology of hepatocellular carcinoma.
- Develop insight into the areas of controversy in the management of hepatocellular carcinoma.
Accreditation
HCC UK First Annual Conference has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 12 category 1 (external) CPD credit(s). Certificate of attendance will be provided to all participants upon request.
Please note this conference has now finished.
